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ABSTRACT
The use of immune checkpoint inhibitors for the treatment of cancer is 
revolutionizing oncology. Amongst these therapeutic agents, antibodies that block 
PD-L1/PD1 interactions between cancer cells and T cells are demonstrating high 
efficacies and low toxicities. Despite all the recent advances, very little is yet known 
on the molecular intracellular signaling pathways regulated by either PD-L1 or PD1. 
Here we review the current knowledge on PD1-dependent intracellular signaling 
pathways, and the consequences of disrupting PD1 signal transduction.
INTRODUCTION
Anti-cancer immunotherapies are finally becoming 
clinically efficacious after many decades of intense 
research and development. Amongst these, antibody-
mediated disruption of programmed death ligand 1 (PD-
L1)/programmed death receptor 1 (PD1) interactions is 
one of the most efficacious with milder adverse effects 
than chemo- and radiotherapy [1]. However, this therapy 
is not successful for all patients and the mechanisms 
underlying anti-PD1 blockade need to be explored. 
Important breakthroughs are continuously being made 
such as the identification of mutations in JAK1, JAK2 
and β2-microglobulin genes associated to primary and 
acquired resistance to PD1 blockade therapy [2, 3].
PD1 is a type I transmembrane protein preferentially 
expressed in immune cells such as T, B and NK cells. PD-
L1 is a member of the B7 family of co-stimulatory/co-
inhibitory molecules of antigen presentation expressed by 
a wide range of cell types, including cancer cells. When 
engaged to its receptor PD-L1, PD1 strongly interferes 
with T cell receptor (TCR) signal transduction through 
several poorly understood molecular mechanisms. PD1 
is made of an extracellular immunoglobulin-like binding 
domain, a transmembrane region and a cytoplasmic domain 
containing an immunoreceptor tyrosine-based inhibitory 
motif (ITIM) and an immunoreceptor tyrosine-based 
switch motif (ITSM) [4]. These motifs are implicated in 
its immunosuppressive effects. Interfering with PD1 signal 
transduction either by antibody blockade or any other 
means enhances T cell functions by potentiating signal 
transduction from the TCR signalosome. Here we review 
the known molecular pathways by which PD1 exerts its 
immunosuppressive functions in T cells.
ANTIGEN PRESENTATION TO THE T 
CELL
T cell activation and expansion is a complex process 
regulated by the interaction of several signaling pathways. 
T cells get activated and expand exponentially after 
encountering antigenic peptides specific for their cognate 
TCRs. Antigenic peptides are presented to T cells usually 
by professional antigen presenting cells (APCs) such as 
dendritic cells (DCs) through a highly regulated process 
called antigen presentation (Figure 1A). APCs capture 
and intracellularly process antigens from pathogens and 
cancer cells into short antigenic peptides which are loaded 
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into major histocompatibility molecules (peptide-MHC 
complexes, or pMHC) and then exposed to the surface. 
There, peptide-MHC complexes bind to the TCR within 
the immunological synapse (Figure 1A). This recognition 
entails the initial step of the activation of the TCR signaling 
cascade (signal 1). However, T cells need at least a second 
co-stimulatory signal to escape from anergy or apoptosis 
[5]. A wide range of stimulatory or inhibitory interactions 
between receptors on the T cell surface and their ligands on 
the surface of the APC lead to signal 2. Thus this signal 2 
will determine the level of T cell activation. Possibly the 
most important co-stimulatory interaction is provided by 
CD80 on the APC binding to CD28 on the T cell. There is 
also a third signal delivered by cytokines which regulates T 
cell differentiation and effector capacities [6]. Then, other 
inhibitory interactions take place between the APC and 
the T cell which modulate the strength and duration of the 
stimulatory signals.
MECHANISMS OF T CELL ACTIVATION
At the molecular level, signal one is delivered 
by kinase-dependent pathways triggered when TCR-
CD3 molecules are bound to pMHC complexes in the 
immunological synapse (Figure 1A). TCR-CD3 and co-
receptor (CD4 or CD8) cross-linking results in tyrosine 
phosphorylation of the TCR-CD3 intracellular domains 
by LCK and FYN kinases (Figure 1B). LCK also 
phosphorylates ZAP70 kinase which is then recruited 
to the CD3ζ chain [7]. ZAP70 starts multiple signaling 
events through LAT phosphorylation and association to 
GRB2 and PLCγ1, culminating with activation of the 
MAPKs ERK and JNK [8] involved in several cellular 
processes such as proliferation, differentiation, motility, 
stress response, apoptosis, and survival. PLCγ1 produces 
diacyl glycerol (DAG) and inositol 1,4,5-triphosphate (IP
3
) 
causing release of calcium ions from the ER and inducing 
NFAT and CREB translocation, which enhances IL2 
transcription. Additionally, ZAP70 phosphorylates p38 
associated to the scaffold protein DLGH1, resulting in its 
autophosphorylation at the activation loop by the so-called 
“alternative p38 activation pathway” which contributes to 
proliferation and cytokine production [9, 10].
Signal 2 (T cell co-stimulation) is exemplified by 
CD80-CD28 interactions between APCs and T cells 
(Figure 1). In this situation, LCK phosphorylates CD28 
intracellular domain, providing a docking site for the 
PI3K complex. PI3K then generates phosphatidylinositol 
3,4,5-triphosphate (PIP
3
), that activates downstream 
kinases including AKT which enhances proliferation and 
survival through the mTOR pathway [11], and PKCθ 
which activates NF-κB and MKK7, required for IL2 
production. T cells require AKT and PKCθ activation to 
acquire full proliferative and effector activities.
Figure 1: Antigen presentation and T cell activation through the T cell receptor signalosome. (A) T cells receive from 
antigen presenting cells (APCs, left of the picture) three signals. APCs present antigenic peptides complexed to MHC molecules (pMHC, 
as indicated) to T cells through binding to their TCR as shown. This interaction triggers intracellular signaling events (signal 1) as indicated 
within the T cell on the right. T cells simultaneously receive additional “positive” and “negative” signals through ligand-receptor interactions 
within the immunological synapse. On top is shown the co-stimulatory interaction driven by CD80-CD28, and below two inhibitory 
interactions between PD-L1/PD1 and CD80-CTLA4. The integration of these signals delivers a second signal regulating the extent of T cell 
activation. A third signal is also provided by cytokines (top). (B) Simplified scheme of the TCR signalosome including the αβ TCR chains 
associated to CD3 molecules as indicated. In this example, only CD3ζ dimers are shown. Signal 1 is initiated through αβ TCR and CD4/
CD8 molecules. This signal depends on LCK activation that phosphorylates CD3 and CD28 cytoplasmic domains. ZAP70 then binds to 
CD3ζ and phosphorylates LAT and p38 as shown. Phosphorylated LAT recruits other enzymes and adaptor molecules as shown which will 
trigger calcium-dependent and MAPK-dependent pathways. Signal 2 depends on PI3K associated to CD28 when associated to CD80 on 
the surface of the APC. PI3K generates PIP
3
 leading to proliferation and survival by regulating AKT-mTOR pathways. CD28 engagement 
prevents apoptosis and acts synergistically with CD3-dependent signals. In green, adaptor molecules. In red, kinases and phospholipase C.
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Nevertheless, there are other associations between 
ligands and receptors in APCs and T cells (Figure 1A). 
Many of these will inhibit T cell activation to modulate 
their activities and have been extensively reviewed 
elsewhere [12].
DIRECT PATHWAYS OF PD1-
DEPENDENT INHIBITION OF TCR 
SIGNAL TRANSDUCTION
Similarly to CD80-CTLA4, PD-L1/PD1 interactions 
are antagonists of CD80-CD28 co-stimulation. PD-
L1-engaged PD1 strongly counteracts TCR signal 
transduction and CD28-co-stimulation even at very 
low PD1 expression levels. As a result, PD1 abrogates 
cytokine production, causes cell cycle arrest and 
decreases transcription of the pro-survival factor Bcl-XL 
[13]. In the direct pathway of TCR inhibition, engaged 
PD1 terminates ZAP70 and PI3K phosphorylation by 
recruiting SHP1 and SHP2 phosphatases to its tyrosine 
phosphorylated ITIM and ITSM motifs [14, 15] (Figure 
2A). However, the specific mode of action is still poorly 
understood. Interestingly, only inactive mutations in the 
phosphorylatable ITSM tyrosine residues abolish PD1-
inhibitory effects, but not in the ITIM motif [13]. SHP1 
can also bind both ITIM and ITSM motifs, while SHP2 
only binds the ITSM [14]. Nevertheless, whether SHP1 
and SHP2 can simultaneously bind the ITSM is yet 
unknown (Figure 2A). It might be possible that binding 
of one prevents binding of the other, behaving like a 
Figure 2: PD1-dependent inhibitory mechanisms. (A) Direct inhibitory mechanisms over the TCR signalosome are shown. The 
figure represents PD1-dependent proximal inhibitory mechanisms, which depend on the recruitment of SHP1 and SHP2 phosphatases as 
shown. These phosphatases inhibit ZAP70 and PI3K activities (blue arrows). Downstream intracellular pathways are also terminated, as 
exemplified in the figure with ERK and PKCθ. (B) Indirect inhibitory mechanisms over TCR signaling and T cell proliferation are shown 
through regulation of CK2 expression and activities. On the left, the PI3K-dependent signaling pathway activating CDK2 and inhibiting 
SMAD3 is shown. Briefly, PIP3 activates AKT leading to production of the ubiquitin ligase SCF that degrades the CDK2 inhibitor Kip1. 
Activated CDK2 triggers cell cycle progression and inactivates SMAD3 by phosphorylation. These pathways are negatively regulated by 
the PTEN phosphatase that degrades PIP
3
. During TCR activation CK2 phosphorylates PTEN with a concomitant decrease in its activities. 
When PD1 is engaged CK2 expression and activities decrease resulting in active PTEN that eliminates PIP
3
 shutting off AKT activation. 
(C) Regulation of TCR surface expression by PD1. PD1 engagement promotes expression of E3 ubiquitin ligases of the CBL family, as 
shown. As indicated, other ligases may be up-regulated as well. These ubiquitin ligases ubiquitylate TCR chains and PI3K, leading to the 
removal of TCRs from the T cell surface, possibly by endocytosis. Thus, T cells cannot respond to antigenic stimulation. (D) Metabolic 
control by PD1. Engaged PD1 alters T cell metabolism from glycolysis to β-oxidation by inhibition of ERK and PI3K-AKT activities. PD1-
stimulated T cells would then metabolically resemble long-lived memory T cells.
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regulatory switch motif similar to the ITSM of CD150 
[16] that may regulate PD1 activities. In agreement with 
this, SHP2 but not SHP1 has been observed associated to 
PD1 in microclusters within the immunological synapse 
[17]. All these evidences support SHP2 as the main 
driver of PD1 inhibitory functions. Unlike SHP2, it is yet 
unclear whether PD1-bound SHP1 really contributes to 
PD1 suppressive function [17]. Nevertheless, SHP1 can 
bind to tyrosine-phosphorylated substrates such as ZAP70 
[18]. It is thought that it could follow a pathway similar 
to termination of “standard” TCR signal transduction 
upon T cell activation through SHP1 dephosphorylating 
ZAP70 [18]. Even so, it has to be remarked that direct 
dephosphorylation of TCR proximal signaling kinases 
by SHP1 and SHP2 associated to PD1 has not yet been 
demonstrated [14].
Engaged PD1 has to be recruited to the 
immunological synapse to exert its activities. Thus, TCR 
engagement with pMHC is sufficient to cause SHP2 
recruitment to PD1, but no T cell suppressive effects are 
exerted unless PD1 is simultaneously ligated [13]. This 
would suggest that PD1-associated phosphatases need the 
proximity to the TCR signalosome to dephosphorylate 
signal transduction kinases in analogy to CTLA4 
recruiting SHP2 to dephosphorylate CD3ζ [13, 19]. The 
consequent inhibition of TCR-dependent distal signaling 
pathways such as ERK are probably the result of direct 
ZAP70 inhibition (Figure 2A).
INDIRECT PATHWAYS OF PD1-
DEPENDENT INHIBITION OF TCR 
SIGNAL TRANSDUCTION
PD-L1-engaged PD1 exerts an additional indirect 
inhibitory control over CD28-costimulation by regulating 
the expression levels and activities of CK2 and cyclin-
dependent kinases (CDKs) (Figure 2B) [20]. In the 
absence of PD1 engagement, TCR activation increases 
CK2 expression that inactivates PTEN by phosphorylation. 
Thus, PTEN cannot dephosphorylate PIP3 produced 
by PI3K allowing TCR signal transduction to proceed. 
Interestingly, engaged PD1 reduces CK2 expression and 
activity with the result of an active PTEN that terminates 
the PI3K-AKT- PKCθ pathway inhibiting T cell growth 
and survival [14].
Engaged PD1 arrests lymphocytes at the G0-G1 
phase through an indirect pathway which inhibits CDKs 
(Figure 2B). The resulting inhibition of AKT and ERK 
either by direct or indirect pathways inhibits transcription 
of SKP2 (part of SCFskp2 ubiquitin ligase) (Figure 1A 
and 1B) [21]. SCFskp2 ubiquitin ligase normally tags the 
CDK2 inhibitor p27Kip1 to proteosomal degradation during 
T cell activation, driving CDK2-dependent cell division. 
Thus, PD1 activities cause an accumulation of p27Kip1 
that associates with CDK2 inhibiting its kinase activities. 
CDK2 inhibition also eliminates the SMAD3 inhibiting 
phosphorylation on Ser213, resulting in the expression 
of SMAD3-responsive genes including p15INK4B (a 
potent inhibitor of CDK4 and CDK6), and repressing 
transcription of the tyrosine phosphatase CDC25A that 
normally removes inhibitory tyrosine phosphorylations of 
CDK4, CDK6 and CDK2 causing T cell arrest [22].
PD1 regulation of TCR down-modulation
Down-modulation and degradation of the TCR 
signalosome is a feature of T cells in cancer patients and 
animal cancer models, especially in tumor-infiltrating 
lymphocytes [23–25]. The most effective way to prevent 
T cells from recognizing antigens is to remove TCRs from 
their surface. Then, T cell function is severely impaired 
as a direct consequence of down-modulated TCRs 
and their associated receptors and signaling mediators 
(signalosome, Figure 1B and 2C). Cancer-associated TCR 
down-modulation is not caused by low affinity interactions 
with tumor antigens. This was demonstrated in a C-MYC-
dependent OVA-expressing hepatocarcinoma murine 
model. Prolonged TCR down-modulation was observed 
in adoptively transferred OVA-specific transgenic CD8 
OTI cells which have high affinity TCRs [26]. Thus, other 
mechanisms must be in place.
PD1 expression is characteristically high in tumor-
infiltrating T cells [27, 28]. Thus, PD-L1-engaged PD1 
contributes to prolonged TCR down-modulation by 
up-regulating the expression of E3-ubiquitin ligases 
CBL-B, c-CBL and ITCH which ultimately causes TCR 
internalization [29, 30] (Figure 2C). Interfering with PD-
L1/PD1 interactions either with blocking antibodies or 
by gene silencing during antigen presentation to T cells 
leads to hyperactivated TCRhigh T cells with decreased 
expression of c-CBL and CBL-b [30].
All the evidence shows that E3 ubiquitin ligases are 
closely linked to regulation of TCR levels and termination 
of TCR-dependent signal transduction. CBL-b and c-CBL 
double-knockout T cells exhibit impaired TCR down-
modulation upon T cell activation, causing hyperactivation 
in the absence of CD28 co-stimulation [31]. CBL-b 
single knock-out T cells also show impaired TCR down-
modulation during physiological immune responses or 
after antigen recognition, similarly to disruption of PD-
L1/PD1 interactions [30, 32]. Mechanistically, CBL-b and 
ITCH cause K33-polyubiquitination of CD3ζ, impairing 
its phosphorylation and the subsequent association of 
ZAP70 [33]. PI3K is also a direct target for CBL-b 
causing proteolysis-independent PI3K inactivation [34]. 
Overall, CBL-b negatively regulates CD28 co-stimulation 
in T cells [35, 36]. Thus, it is highly likely that the strong 
CD28-counteracting activities of PD1 could be partly 
caused by E3 ubiquitin ligases. It is worth noting that PD-
L1 blockade also inhibits down-modulation of additional T 
cell activation markers such as ICOS, making PD1-driven 
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receptor down-modulation a major regulatory mechanism 
of T cell functions [30, 37].
PD1 control of T cell metabolism
It is well known that T cell activation requires 
a fast energy increase which is achieved by glycolysis-
dependent metabolism. Interestingly, engaged PD1 may be 
fundamental to rapidly shift the metabolic reprogramming 
of T cells from an effector to a long-lived memory-like 
phenotype with a shift from increased glycolysis towards 
fatty acid β-oxidation [38, 39] (Figure 2D). It is thought 
that this metabolic change might extend the lifespan of 
PD1high T cells. The exact molecular mechanisms are still 
unclear, although it could be mediated by PD1-dependent 
inhibition of PI3K and ERK. Thus, simultaneous 
inhibition of PI3K/AKT and ERK recapitulated some of 
PD1-dependent metabolic changes [39]. It is remarkable 
that PD1-engaged T cells closely resemble long-lived 
memory T cells from a metabolic point of view, when the 
current view is that sustained PD1 stimulation leads to T 
cell exhaustion. The implications of PD1 signaling in T 
cell differentiation will probably expand the accepted roles 
of PD1 as an immunosuppressive pathway.
FUNCTIONAL CONSEQUENCES OF PD-
L1/PD1 DISRUPTION
The immune response is highly complex, and many 
factors can influence the outcome of immunotherapies. 
In addition, response patterns of PD-L1/PD1 blockade 
therapy are strikingly different from those of chemotherapy 
or targeted therapies. Targeted therapies cause fast tumor 
remissions but with prompt acquisition of resistance 
(Figure 3). In contrast, patients who respond to PD-L1/
PD1 blockade show significant and durable responses, 
although a delay of even months can be observed. From 
a clinical point of view there is a strong need to identify 
biomarkers that can predict the outcome of PD-L1/PD1 
blockade. It is naturally assumed that PD-L1 expression 
in cancer cells would correlate with therapeutic outcome. 
However, the results from clinical trials differ on the 
usefulness of PD-L1 expression as a biomarker, as patients 
with PD-L1-positive and PD-L1-negative tumors may 
benefit from the treatment [1].
To explain the apparent contradictions observed in 
clinical trials we have first to consider that PD-L1/PD1 
functions are context-specific. The regulatory functions 
of this interaction take place in at least three stages: 
(i) During antigen presentation to T cells [30]; (ii) in 
peripheral tissues to maintain tolerance [40, 41], and (iii) 
at the inflammation site to dampen excessive autoreactive 
damage [4, 40]. Thus, systemic disruption of PD-L1/PD1 
interactions in cancer patients will unleash several events 
contributing to therapeutic efficacy but also to side effects:
Hyperactivation of naïve T cells undergoing 
antigen presentation
Systemic PD-L1/PD1 blockade very likely 
affects naïve T cells undergoing antigen presentation 
by professional APCs in lymphoid organs, as PD-L1 is 
Figure 3: Immunotherapies and targeted therapies display distinct patterns of response. The graph displays a model of 
responses for immunotherapies and targeted therapies such as kinase inhibitors. The percentage of survival is plotted over time after the 
initial treatment. While targeted therapies exhibit fast anti-tumor effects, tumors acquire resistance to treatments. This is exemplified as a 
sudden drop of survival as indicated within the dotted square on the right. In contrast, immunotherapies show a significant group of patients 
that are intrinsically resistant to therapy, evidenced as an initial sudden drop in survival as indicated within the dotted square on the left. 
Then, long-term survivors are found with durable responses. So far, there are not effective biomarkers discriminating patients that could 
benefit from immunotherapies from those with intrinsic resistance.
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normally highly expressed by professional APCs such as 
DCs [30, 40, 42]. PD-L1 expression is strongly up-regulated 
following DC maturation probably as a regulatory negative 
feedback mechanism. However, PD-L1/PD1 interactions 
play a critical role in physiological T cell activation during 
antigen presentation. Engaged PD1 in T cells during antigen 
presentation by DCs causes prolonged ligand-induced TCR 
down-modulation, which is followed by exponential clonal 
expansion rather than permanent T cell inactivation [30]. 
TCR surface expression is recovered within two weeks 
when a significant number of antigen-specific T cells have 
accumulated, ready to exert cytotoxic activities over target 
cells [43]. Disruption of PD-L1/PD1 interactions at this 
stage leads to hyperactivated TCRhigh effector T cells which 
mediate an early immune attack [43, 44]. The resulting 
expansion of activated T cells from the pool of naïve T 
cells may enhance the anti-tumor response. Some evidence 
in preclinical models has been recently published which 
suggests that this could in fact be the case [45]. Moreover, 
interference of PD-L1/PD1 interactions during antigen 
presentation by DCs also favors that T cells do not lose their 
capacities to simultaneously express more than one cytokine 
(such as TNF-α, IL2, IFN-γ and MIP-1β) [42], in agreement 
with the capacities of PD-L1/PD1 blockade to revert (or 
prevent) T cell exhaustion [46].
Recovery of T cell functions of cancer-specific 
memory T cells
Tumors are infiltrated with an array of immune cells 
which includes memory PD1+ T cells. These T cells are 
antigen-experienced but they have been inactivated by the 
tumor [47]. Reactivation of these experienced memory 
T cells might be the cause of the efficacy of PD-L1/
PD1 blockade in patients with PD-L1-positive tumors 
[48]. These intra-tumor T cells usually lack expression 
of the TCR signalosome, and PD-L1/PD1 blockade may 
contribute to the recovery of TCR surface expression 
and signal transduction. The reactivation of this pool of 
antigen-experienced T cells seems to be the driver of the 
efficacy of PD-L1/PD1 blockade in human therapy [49]. 
In fact, T cell infiltration can be used as a predicting factor. 
Tumor infiltration with PD1high CTLA4high exhausted CD8 
T cells can be an accurate predictor of response to anti-
PD1 therapy in melanoma [50, 51].
Polyclonal expansion of T cells in peripheral 
tissue
PD-L1/PD1 interactions in peripheral tissues 
between many cell types and T cells ensure that circulating 
T cells do not react with autoantigens. This is also 
reinforced by the decreased expression of surface TCR 
in activated T cells during the clonal expansion phase 
[30, 43]. However, systemic disruption of PD-L1/PD1 
may have a significant impact on antigen recognition in 
peripheral tissue. In fact, it has been shown that local PD-
L1 silencing in peripheral tissue expands polyclonal CD8 
T cells [41] suggesting that systemic administration of 
PD-L1/PD1 blocking antibodies may expand a polyclonal 
pool of T cells following antigen recognition in peripheral 
tissues. The nature of these T cells has not been elucidated 
yet, but these reactivated T cells may be behind of some 
of the autoreactive adverse events associated to treatments 
with immune checkpoint inhibitors [52, 53]. Nevertheless, 
these T cells may also contain a significant pool of tumor 
antigen-specific cells that can be recruited to the tumor 
environment.
Direct effects over cancer cells
The current conventional view states that direct 
disruption of PD-L1/PD1 interactions between cancer 
and T cells is behind the therapeutic efficacy of blocking 
antibodies. However, PD-L1/PD1 interactions may also 
take place between melanoma cells in the absence of T cells 
[54]. This suggests that a minor population of melanoma 
cells may express some PD1 on their surface. Elimination 
of PD1 expression in murine mouse melanoma models 
and also in human xenografts inhibited cancer cell growth. 
Antibody-mediated disruption of this interaction directly 
delayed tumor growth without the need of enhanced T cell 
anti-tumor activities. The same result was achieved by either 
PD1 silencing or PD-L1 silencing in tumor cells [41, 54]. 
Thus, intercellular PD-L1/PD1 interactions transmit survival 
signals to cancer cells and promote in vivo tumor growth 
Therefore, disruption of PD-L1/PD1 interactions between 
cancer cells will delay tumor growth while anti-cancer T 
cells become activated [41].
CONCLUSIONS
PD-L1/PD1 antibody blockade has yielded 
encouraging results for the treatment of a wide range 
of cancer types. The exact molecular and cellular 
mechanisms behind its potent anti-cancer activities are 
still poorly understood. PD1 engagement by PD-L1 
leads to rapid termination of TCR intracellular signaling 
and inhibition of T cell proliferation through direct and 
indirect mechanisms. Most of the evidence points to SHP-
2 recruitment as the main driver of all these mechanisms. 
However, it has to be mentioned that many experimental 
evidences so far come from immortal Jurkat T cells. 
Therefore, it cannot be ruled out that PD1 employs other 
yet unknown pathways to disrupt TCR signaling cascades 
and alter T cell metabolism.
A key issue with PD-L1/PD1 blockade therapy 
is the identification of predictive markers of response. 
Recently, inactivating mutations in the interferon signal 
transduction pathway and in class I antigen presentation 
have been shown to correlate with both primary and 
adaptive resistance to anti-PD1 therapy treatment [2, 3]. 
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Therefore, there is a frantic need to identify alternative 
targets susceptible of therapeutic intervention that could 
minimize cancer cell escape. The tumor environment is 
a complex system in which many cell types cooperate to 
protect it, including myeloid-derived suppressor cells, 
tumor-infiltrating macrophages, regulatory T cells and 
other cell types of the tumor stroma [55–58]. Many of 
these cell types utilize the PD-L1/PD1 signaling axis to 
suppress anti-tumor immune responses. Therefore, the 
understanding of the mechanisms behind PD1-dependent 
cell suppression will surely uncover a number of novel 
targets susceptible of therapeutic intervention.
During the last years, therapies targeting main 
regulatory components of the immune synapse have been 
developed and are progressively displacing chemotherapy 
in different clinical contexts [1, 51, 59, 60]. Preliminary 
results from the simultaneous blockade of PD1 and CTLA4 
in metastatic melanoma were also published, and now this 
combination is being tested in many different neoplasms 
[61, 62]. The better understanding of the signaling pathways 
underlying the immune response has revealed potential 
targets that might improve the efficacy of the current 
treatments. Many new drugs are now under evaluation, both 
potentiating co-stimulatory molecules such as 4-1BB, OX40, 
CD27, CD40, GITR, or blocking immunosuppressive 
proteins including LAG-3 or VISTA [63–65]. Their efficacy 
in combination with PDL1/PD1 blockade and CTLA4-
targeted therapies will surely be reported in the near future.
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